Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease

Affiliations

¹ Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
² Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.
³ Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
⁴ University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Free article

Randomized Controlled Trial

Alex George et al. Am J Hematol. 2020 Sep.

Free article

. 2020 Sep;95(9):E242-E244.

doi: 10.1002/ajh.25883. Epub 2020 Jul 4.

¹ Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
² Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.
³ Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
⁴ University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

No abstract available

References

1. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311-323.
1. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program. 2009;2009:62-69.
1. Ware RE, Mortier NA, Smeltzer MP, et al. Predicting hydroxyurea responses in children with sickle cell anemia. Blood. 2011;118(21):2131.
1. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am. 2010;24(1):199-214.
1. Ballas SK. Defining the phenotypes of sickle cell disease. Hemoglobin. 2011;35(5-6):511-519.